Two new studies from the Conference on Retroviruses and Opportunistic Infections highlight the issue of HCV reinfection in HIV+ MSM in Europe and the US.
Opioids and infectious diseases, PrEP and STI risk, new oral Rx for C diff, and a shortage of ID specialists. We summarize studies, commentaries, and reports on these topics and more.
Sexually transmitted infection cases have reached an all-time high at an alarming speed. Test your knowledge of different treatment options with our new case challenge.
How do we combat waning human immunity? Our slide show summarizes 5 new reports that suggest it’s essential to figure that out.
Sample: A 36-year-old former IV drug user tests positive for chronic HCV and wants to know the likelihood of cure if she completes treatment. How should you counsel her?
A new study found that direct-acting antiviral treatment is linked to decreased risk of liver cancer, liver-related death, and all-cause mortality.
Results of the largest study of its kind may help quell longstanding controversy surrounding the impact of DAA therapy on recurrence of HCC.
CDC guidance on hepatitis C screening is mandatory primary care reading. Test your recall with these 5 questions on CDC recommendations.
A new study models the impact of 4 key public health interventions on global HCV burden to see if WHO elimination targets are realistic.
A first-of-its-kind study found that among cirrhosis patients with and without HIV-coinfection, liver function improved >50% in each cohort.